Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Advanced Therapy Medicinal Products CDMO Market, by Indication
1.4.2 Europe Advanced Therapy Medicinal Products CDMO Market, by Product
1.4.3 Europe Advanced Therapy Medicinal Products CDMO Market, by Phase
1.4.4 Europe Advanced Therapy Medicinal Products CDMO Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Acquisitions and Mergers : 2019, Jan – 2022, Aug) Leading Players
Chapter 4. Europe Advanced Therapy Medicinal Products CDMO Market by Indication
4.1 Europe Oncology Market by Country
4.2 Europe Cardiology Market by Country
4.3 Europe Central Nervous System & Musculoskeletal Market by Country
4.4 Europe Infectious Disease Market by Country
4.5 Europe Dermatology Market by Country
4.6 Europe Endocrine, Metabolic, Genetic Market by Country
4.7 Europe Immunology & Inflammation Market by Country
4.8 Europe Ophthalmology Market by Country
4.9 Europe Hematology Market by Country
4.1 Europe Gastroenterology Market by Country
4.11 Europe Others Market by Country
Chapter 5. Europe Advanced Therapy Medicinal Products CDMO Market by Product
5.1 Europe Gene Therapy Market by Country
5.2 Europe Cell Therapy Market by Country
5.3 Europe Tissue Engineered & Others Market by Country
Chapter 6. Europe Advanced Therapy Medicinal Products CDMO Market by Phase
6.1 Europe Phase I Market by Country
6.2 Europe Phase II Market by Country
6.3 Europe Phase III Market by Country
6.4 Europe Phase IV Market by Country
Chapter 7. Europe Advanced Therapy Medicinal Products CDMO Market by Country
7.1 Germany Advanced Therapy Medicinal Products CDMO Market
7.1.1 Germany Advanced Therapy Medicinal Products CDMO Market by Indication
7.1.2 Germany Advanced Therapy Medicinal Products CDMO Market by Product
7.1.3 Germany Advanced Therapy Medicinal Products CDMO Market by Phase
7.2 UK Advanced Therapy Medicinal Products CDMO Market
7.2.1 UK Advanced Therapy Medicinal Products CDMO Market by Indication
7.2.2 UK Advanced Therapy Medicinal Products CDMO Market by Product
7.2.3 UK Advanced Therapy Medicinal Products CDMO Market by Phase
7.3 France Advanced Therapy Medicinal Products CDMO Market
7.3.1 France Advanced Therapy Medicinal Products CDMO Market by Indication
7.3.2 France Advanced Therapy Medicinal Products CDMO Market by Product
7.3.3 France Advanced Therapy Medicinal Products CDMO Market by Phase
7.4 Russia Advanced Therapy Medicinal Products CDMO Market
7.4.1 Russia Advanced Therapy Medicinal Products CDMO Market by Indication
7.4.2 Russia Advanced Therapy Medicinal Products CDMO Market by Product
7.4.3 Russia Advanced Therapy Medicinal Products CDMO Market by Phase
7.5 Spain Advanced Therapy Medicinal Products CDMO Market
7.5.1 Spain Advanced Therapy Medicinal Products CDMO Market by Indication
7.5.2 Spain Advanced Therapy Medicinal Products CDMO Market by Product
7.5.3 Spain Advanced Therapy Medicinal Products CDMO Market by Phase
7.6 Italy Advanced Therapy Medicinal Products CDMO Market
7.6.1 Italy Advanced Therapy Medicinal Products CDMO Market by Indication
7.6.2 Italy Advanced Therapy Medicinal Products CDMO Market by Product
7.6.3 Italy Advanced Therapy Medicinal Products CDMO Market by Phase
7.7 Rest of Europe Advanced Therapy Medicinal Products CDMO Market
7.7.1 Rest of Europe Advanced Therapy Medicinal Products CDMO Market by Indication
7.7.2 Rest of Europe Advanced Therapy Medicinal Products CDMO Market by Product
7.7.3 Rest of Europe Advanced Therapy Medicinal Products CDMO Market by Phase
Chapter 8. Company Profiles
8.1 Thermo Fisher Scientific, Inc. (Patheon, Inc.)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 SWOT Analysis
8.2 AGC Biologics, Inc. (AGC, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Acquisition and Mergers:
8.2.5.3 Geographical Expansions:
8.3 Catalent, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional & Segmental Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Acquisition and Mergers:
8.4 Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation)
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expenses
8.5 WuXi AppTec Co., Ltd. (WuXi Advanced Therapies)
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental Analysis
8.5.4 Recent strategies and developments:
8.5.4.1 Product Launches and Product Expansions:
8.5.4.2 Acquisition and Mergers:
8.5.4.3 Partnerships, Collaborations, and Agreements:
8.6 Lonza Group AG
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Geographical Expansions:
8.7 Celonic AG (JRS PHARMA GmbH & Co. KG)
8.7.1 Company Overview
8.8 Bio Elpida (Polyplus-transfection SA.)
8.8.1 Company Overview
8.9 Rentschler Biopharma SE
8.9.1 Company Overview
8.9.2 Recent strategies and developments:
8.9.2.1 Partnerships, Collaborations, and Agreements:
8.9.2.2 Acquisition and Mergers:
Unique Offerings 